Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024 ...Middle East

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical development Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a...

Hence then, the article about ariceum therapeutics presents outstanding data on its first in class radiopharmaceutical drug 225ac satoreotide at the european association of nuclear medicine 2024 was published today ( Tuesday 22/10/2024 - 10:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024 )

Also on site :

• Today’s NYT ‘Strands’ Hints, Spangram and Answers for Wednesday, October 21, 2026
• Italy approves sweeping security measures in response to protests
• In 1928, a Former Hershey Dairy Worker Started Making Peanut Butter Cups in His Basement; 35 Years Later, His Sons Sold Reese’s to Hershey for $23.5 Million